314 related articles for article (PubMed ID: 27447547)
1. Maintenance therapy of childhood acute lymphoblastic leukemia revisited-Should drug doses be adjusted by white blood cell, neutrophil, or lymphocyte counts?
Schmiegelow K; Nersting J; Nielsen SN; Heyman M; Wesenberg F; Kristinsson J; Vettenranta K; Schrøeder H; Weinshilboum R; Jensen KL; Grell K; Rosthoej S
Pediatr Blood Cancer; 2016 Dec; 63(12):2104-2111. PubMed ID: 27447547
[TBL] [Abstract][Full Text] [Related]
2. Measures of 6-mercaptopurine and methotrexate maintenance therapy intensity in childhood acute lymphoblastic leukemia.
Nielsen SN; Grell K; Nersting J; Frandsen TL; Hjalgrim LL; Schmiegelow K
Cancer Chemother Pharmacol; 2016 Nov; 78(5):983-994. PubMed ID: 27600880
[TBL] [Abstract][Full Text] [Related]
3. Myelotoxicity, pharmacokinetics, and relapse rate with methotrexate/6-mercaptopurine maintenance therapy of childhood acute lymphoblastic leukemia.
Schmiegelow K; Ifversen M
Pediatr Hematol Oncol; 1996; 13(5):433-41. PubMed ID: 10897815
[TBL] [Abstract][Full Text] [Related]
4. Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia.
Schmiegelow K; Björk O; Glomstein A; Gustafsson G; Keiding N; Kristinsson J; Mäkipernaa A; Rosthøj S; Szumlanski C; Sørensen TM; Weinshilboum R
J Clin Oncol; 2003 Apr; 21(7):1332-9. PubMed ID: 12663723
[TBL] [Abstract][Full Text] [Related]
5. 6-mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia.
Schmiegelow K; Bretton-Meyer U
Leukemia; 2001 Jan; 15(1):74-9. PubMed ID: 11243403
[TBL] [Abstract][Full Text] [Related]
6. DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial.
Nielsen SN; Grell K; Nersting J; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Vaitkeviciene G; Pruunsild K; Hjalgrim LL; Schmiegelow K
Lancet Oncol; 2017 Apr; 18(4):515-524. PubMed ID: 28258828
[TBL] [Abstract][Full Text] [Related]
7. Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity.
Levinsen M; Rosthøj S; Nygaard U; Heldrup J; Harila-Saari A; Jonsson OG; Bechensteen AG; Abrahamsson J; Lausen B; Frandsen TL; Weinshilboum RM; Schmiegelow K
Cancer Chemother Pharmacol; 2015 Jan; 75(1):59-66. PubMed ID: 25347948
[TBL] [Abstract][Full Text] [Related]
8. Methotrexate and 6-mercaptopurine maintenance therapy for childhood acute lymphoblastic leukemia: dose adjustments by white cell counts or by pharmacokinetic parameters?
Schmiegelow K; Schrøder H; Schmiegelow M
Cancer Chemother Pharmacol; 1994; 34(3):209-15. PubMed ID: 8004753
[TBL] [Abstract][Full Text] [Related]
9. Mercaptopurine metabolite levels are predictors of bone marrow toxicity following high-dose methotrexate therapy of childhood acute lymphoblastic leukaemia.
Vang SI; Schmiegelow K; Frandsen T; Rosthøj S; Nersting J
Cancer Chemother Pharmacol; 2015 May; 75(5):1089-93. PubMed ID: 25788208
[TBL] [Abstract][Full Text] [Related]
10. Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology.
Schmiegelow K; Schrøder H; Gustafsson G; Kristinsson J; Glomstein A; Salmi T; Wranne L
J Clin Oncol; 1995 Feb; 13(2):345-51. PubMed ID: 7531219
[TBL] [Abstract][Full Text] [Related]
11. The circadian schedule for childhood acute lymphoblastic leukemia maintenance therapy does not influence event-free survival in the NOPHO ALL92 protocol.
Clemmensen KK; Christensen RH; Shabaneh DN; Harila-Saari A; Heyman M; Jonsson OG; Wesenberg F; Rosthøj S; Schmiegelow K;
Pediatr Blood Cancer; 2014 Apr; 61(4):653-8. PubMed ID: 24265159
[TBL] [Abstract][Full Text] [Related]
12. The degree of myelosuppression during maintenance therapy of adolescents with B-lineage intermediate risk acute lymphoblastic leukemia predicts risk of relapse.
Schmiegelow K; Heyman M; Gustafsson G; Lausen B; Wesenberg F; Kristinsson J; Vettenranta K; Schroeder H; Forestier E; Rosthoej S;
Leukemia; 2010 Apr; 24(4):715-20. PubMed ID: 20130603
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of methotrexate and 6-mercaptopurine dosage during maintenance chemotherapy for childhood acute lymphoblastic leukemia.
Schmiegelow K
Pediatr Hematol Oncol; 1991; 8(4):301-12. PubMed ID: 1782110
[TBL] [Abstract][Full Text] [Related]
14. Maintenance chemotherapy for childhood acute lymphoblastic leukemia: should dosage be guided by white blood cell counts?
Schmiegelow K; Pulczynska MK
Am J Pediatr Hematol Oncol; 1990; 12(4):462-7. PubMed ID: 2285127
[TBL] [Abstract][Full Text] [Related]
15. Hepatic sinusoidal obstruction syndrome during maintenance therapy of childhood acute lymphoblastic leukemia is associated with continuous asparaginase therapy and mercaptopurine metabolites.
Toksvang LN; De Pietri S; Nielsen SN; Nersting J; Albertsen BK; Wehner PS; Rosthøj S; Lähteenmäki PM; Nilsson D; Nystad TA; Grell K; Frandsen TL; Schmiegelow K
Pediatr Blood Cancer; 2017 Sep; 64(9):. PubMed ID: 28423235
[TBL] [Abstract][Full Text] [Related]
16. Role of TPMT and ITPA variants in mercaptopurine disposition.
Gerbek T; Ebbesen M; Nersting J; Frandsen TL; Appell ML; Schmiegelow K
Cancer Chemother Pharmacol; 2018 Mar; 81(3):579-586. PubMed ID: 29387964
[TBL] [Abstract][Full Text] [Related]
17. Relapse in acute lymphoblastic leukemia as a function of white blood cell and absolute neutrophil counts during maintenance chemotherapy.
Lucas K; Gula MJ; Blatt J
Pediatr Hematol Oncol; 1992; 9(2):91-7. PubMed ID: 1524994
[TBL] [Abstract][Full Text] [Related]
18. Maintenance chemotherapy for childhood acute lymphoblastic leukemia: relation of bone-marrow and hepatotoxicity to the concentration of methotrexate in erythrocytes.
Schmiegelow K; Schrøder H; Pulczynska MK; Hejl M
Cancer Chemother Pharmacol; 1989; 25(1):65-9. PubMed ID: 2591003
[TBL] [Abstract][Full Text] [Related]
19. Mercaptopurine/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction.
Schmiegelow K; Nielsen SN; Frandsen TL; Nersting J
J Pediatr Hematol Oncol; 2014 Oct; 36(7):503-17. PubMed ID: 24936744
[TBL] [Abstract][Full Text] [Related]
20. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia.
Relling MV; Hancock ML; Boyett JM; Pui CH; Evans WE
Blood; 1999 May; 93(9):2817-23. PubMed ID: 10216075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
